Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

2.9K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

598
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
598
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

753
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

1.0K
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
1.0K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Novel histone deacetylase inhibitor, CS014, attenuates in vivo thrombosis while maintaining hemostasis.

Journal of thrombosis and haemostasis : JTH·2025
Same author

CS1, a controlled-release formulation of valproic acid, for the treatment of patients with pulmonary arterial hypertension: Rationale and design of a Phase 2 clinical trial.

Pulmonary circulation·2024
Same author

The oxylipin analog CS585 prevents platelet activation and thrombosis through activation of the prostacyclin receptor.

Blood·2023
Same author

Antihypertensive treatment in people of very old age with frailty: time for a paradigm shift?

Journal of hypertension·2023
Same author

Pharmacoepigenetics of hypertension: genome-wide methylation analysis of responsiveness to four classes of antihypertensive drugs using a double-blind crossover study design.

Epigenetics·2022
Same author

Effects of Randomized Controlled Infancy-Onset Dietary Intervention on Leukocyte Telomere Length-The Special Turku Coronary Risk Factor Intervention Project (STRIP).

Nutrients·2021

相关实验视频

Updated: May 3, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.8K

洛萨坦对孤立的静脉缩高血压和左心室缩患者心血管发病率和死亡率的影响:洛萨坦干预终点减少 (LIFE) 副研究.

Sverre E Kjeldsen1, Björn Dahlöf, Richard B Devereux

  • 1Department of Internal Medicine, Dividsion of Hypertension, University of Michigan, Ann Arbor, USA.

JAMA
|September 24, 2002
PubMed
概括

洛萨坦与阿提诺洛尔相比,在患有隔离性静脉缩高血压和左心室缩症的患者中表现出更好的结果. 这包括减少心血管事件,中风和死亡率,具有更好的耐受性.

更多相关视频

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
08:15

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

18.9K
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

6.9K

相关实验视频

Last Updated: May 3, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.8K
Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
08:15

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

18.9K
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

6.9K

科学领域:

  • 心脏病学 心脏病学
  • 药理学 药理学是指药理学的学科.
  • 临床试验 临床试验

背景情况:

  • 隔离性缩性高血压 (ISH) 是心血管事件的重要危险因素.
  • 药物干预已在管理ISH方面显示出好处.
  • 左心室缩 (LVH) 是高血压患者常见的并发症.

研究的目的:

  • 为了比较洛萨坦与阿提诺洛尔在ISH和心电图记录左心室缩 (ECG-LVH) 的患者中的疗效.
  • 评估洛萨坦和阿提诺洛尔对心血管结果的影响,包括死亡,中风和心肌梗塞.

主要方法:

  • 这是一项双盲,随机,并行组研究,涉及1326名55-80岁的ISH和ECG-LVH患者.
  • 患者每天接受一次洛萨坦或阿提诺洛尔,并以基亚胺为第二剂,平均接受了4.7年.
  • 主要终点是心血管死亡,中风或心肌梗塞的复合结果.

主要成果:

  • 与阿提诺洛尔相比,洛萨坦将复合终点降低了25% (未调整的RR,0.71;P=.02).
  • 洛萨坦在心血管死亡率 (RR,0.54;P=.01) 和中风 (RR,0.60;P=.02) 中显著降低.
  • 洛萨坦还降低了新发糖尿病 (RR,0.62;P=.04) 和总死亡率 (RR,0.72;P=.046),并显示了ECG-LVH的更大降低 (P<.001).

结论:

  • 洛萨坦在治疗隔离性缩性高血压和ECG-LVH患者方面优于阿诺洛.
  • 洛萨坦在这种患者群体中提供了显著的心血管和死亡率益处.
  • 洛萨坦的耐受性比阿提诺洛尔更好.